Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840369 | 0.94 | GCGR (0.38) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL4433512 | 0.83 | MAPT (0.46) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL3835353 | 0.79 | MAPT (0.50) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL949686 | 0.78 | MAPT (0.45) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL4508229 | 0.74 | MAPT (0.44) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL4598474 | 0.72 | MAPT (0.39) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL4223386 | 0.71 | GCGR (0.45) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL950747 | 0.70 | MAPT (0.62) | MAPTTP53ALDH1A1HTTGAA | |
| SCHEMBL4443509 | 0.69 | GCGR (0.45) | GCGRMAPTTP53ALDH1A1HTT | |
| SCHEMBL4513439 | 0.69 | MAPT (0.41) | GCGRMAPTTP53GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2009-12-31 | — | — | US | disclosed |
| EP-2108018-A2 | 8-OXA-1,4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4,8-TRIAZASPIRO [4,5] DEC-3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Glaxo Group Limited (GB) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008092877-A2 | 8-OXA-1, 4-DIAZASPIRO [4,5] DEC-3-EN-1-YL AND 1,4, 8-TRIAZASPIRO [4,5] DEC- 3-EN-1-YL ACETAMIDES AS GLYTI TRANSPORTER INHIBITORS IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325993-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC1A2, SLC6A2 | GCGR 725/4885MAPT 92/4885TP53 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.